# US 2026/0151467 A1 · Method for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0151467 A1
- Document ID: US20260151467A1
- Status: Published application
- Kind: A1
- Application number: 19/289,937
- Filed: 2025-08-04
- Published: 2026-06-04
- Earliest claimed: 2018-07-12
- Assignees: Children's Medical Center Corporation
- Applicants: The Children's Medical Center Corporation
- Inventors: Alejandro GUTIERREZ; Laura HINZE
- Web page: https://patentgrep.com/patent/US20260151467A1

## CPC

- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/426: 1,3-Thiazoles
- A61K 31/433: Thidiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 35/00: Antineoplastic agents
- C12Y 305/01001: Asparaginase (3.5.1.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an asparaginase and an agent that inhibits GSK3α. Another aspect of the invention relates to administering an asparaginase to a subject having cancer that comprises an inactivating mutation in GSK3α.

## Claims

### Claim 1

1) A method for treating cancer, the method comprising: administering to a subject having cancer an asparaginase, wherein the cancer comprises a mutation that results in inhibition of GSK3α.

### Claim 2 (depends on 1)

2) The method of claim 1, wherein the asparaginase is selected from the group consisting of: L-asparaginase (Elspar), pegaspargase (PEG-asparaginase; Oncaspar), SC-PEG asparaginase (Calaspargase pegol), and Erwinia asparaginase (Erwinaze).

### Claim 3 (depends on 1)

3) The method of claim 1, wherein the mutation results in the activation of the WNT signaling pathway in the cancer call.

### Claim 4 (depends on 1)

4) The method of claim 1, wherein the mutation is in a gene selected the group consisting of: R-spondin1 (RSPO1), R-spondin 2 (RSPO2), R-spondin 3 (RSPO3), R-spondin4 (RSPO4), ring finger protein 43 (RNF43), and glycogen synthase kinase 3 alpha (GSK3A, more commonly referred to as GSK3α).

### Claim 5 (depends on 1)

5) The method of claim 1, wherein the mutation alters the expression of a gene selected the group consisting of: R-spondin1 (RSPO1), R-spondin 2 (RSPO2), R-spondin 3 (RSPO3), R-spondin4 (RSPO4), ring finger protein 43 (RNF43), and glycogen synthase kinase 3 alpha (GSK3A, more commonly referred to as GSK3α).

### Claim 6 (depends on 1)

6) The method of claim 1, wherein the cancer is selected from the list consisting of: a carcinoma, a melanoma, a sarcoma, a myeloma, a leukemia, or a lymphoma.

### Claim 7 (depends on 1)

7) The method of claim 1, wherein the cancer is a solid tumor.

### Claim 8 (depends on 1)

8) The method of claim 1, wherein the cancer is colon or pancreatic cancer.

### Claim 9 (depends on 1)

9) The method of claim 1, wherein the cancer is metastatic.

### Claim 10 (depends on 1)

10) The method of claim 1, wherein prior to administration, the subject is identified as having a cancer comprising a mutation that results in inhibition of GSK3α.

### Claim 11 (depends on 10)

11) The method of claim 10, wherein the mutation is identified in a biological sample obtained from the subject.

### Claim 12 (depends on 11)

12) The method of claim 11, wherein the biological sample is a tissue sample or a blood sample.

### Claim 13 (depends on 1)

13) The method of claim 1, wherein the cancer is resistant to a cancer therapy.

### Claim 14 (depends on 1)

14) The method of claim 1, wherein the cancer relapsed following a cancer therapy.

### Claim 15 (depends on 14)

15) The method of claim 14, wherein the cancer therapy is chemotherapy, radiation therapy, immunotherapy, surgery, hormone therapy, stem cell therapy, targeted therapy, gene therapy, and precision therapy.

### Claim 16

16) A method of treating cancer, the method comprising:
a. obtaining a biological sample from a subject having cancer;
b. assaying the sample and identifying the cancer as having a mutation that results in inhibition of GSK3α; and
c. administering an asparaginase to a subject who has been identified as having cancer having a mutation that results in inhibition of GSK3α.

### Claim 17

17) A method of treating cancer, the method comprising:
a. receiving the results of an assay that identifies a subject as having a cancer having a mutation that results in inhibition of GSK3α; and
b. administering an asparaginase to a subject who has been identified as having cancer having a mutation that results in inhibition of GSK3α.
